ORBIMED ADVISORS LLC Insider Trading Transactions
Get free email notifications about insider trading for ORBIMED ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ORBIMED ADVISORS LLC. ORBIMED ADVISORS LLC is Director in AMARIN CORP PLC\UK ($AMRN) and 10% Owner in AMBIT BIOSCIENCES CORP ($AMBI) and 10% Owner in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Director in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Director in Anthera Pharmaceuticals Inc ($ANTH) and 10% Owner in COMPLETE GENOMICS INC ($GNOM) and 10% Owner in Pacira Pharmaceuticals, Inc. ($PCRX) and 10% Owner in Relypsa Inc ($RLYP) and 10% Owner in Mirati Therapeutics, Inc. ($MYG).
Latest Insider Trading Transactions of ORBIMED ADVISORS LLC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMRN, AMBI, ANTH, GNOM, ICPT, MYG, PCRX, RLYP
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 05 2015 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 20.00 | 100,000 | 2,000,000 | 1,267,000 | 1.2 M to 1.3 M (+8.57 %) |
Jul 01 2014 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 20.04 | 5,000 | 100,200 | 1,167,000 | 1.2 M to 1.2 M (-0.43 %) |
Jul 01 2014 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 21.11 | 4,717 | 99,576 | 1,172,000 | 1.2 M to 1.2 M (-0.40 %) |
Jul 01 2014 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 20.33 | 9,283 | 188,723 | 1,176,717 | 1.2 M to 1.2 M (-0.78 %) |
Jul 01 2014 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 23.09 | 9,212 | 212,705 | 1,186,000 | 1.2 M to 1.2 M (-0.77 %) |
Jul 01 2014 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 21.79 | 79,120 | 1,724,025 | 1,195,212 | 1.3 M to 1.2 M (-6.21 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.34 | 400 | 120,936 | 1,485,324 | 1.5 M to 1.5 M (-0.03 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.36 | 5,400 | 1,627,344 | 1,485,724 | 1.5 M to 1.5 M (-0.36 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.11 | 45,058 | 13,522,356 | 1,491,124 | 1.5 M to 1.5 M (-2.93 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 299.13 | 10,400 | 3,110,952 | 1,536,182 | 1.5 M to 1.5 M (-0.67 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.26 | 1,990 | 591,547 | 1,546,582 | 1.5 M to 1.5 M (-0.13 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.59 | 10,010 | 2,968,866 | 1,548,572 | 1.6 M to 1.5 M (-0.64 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 295.52 | 25,442 | 7,518,620 | 1,558,582 | 1.6 M to 1.6 M (-1.61 %) |
Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.67 | 12,558 | 3,700,466 | 1,584,024 | 1.6 M to 1.6 M (-0.79 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 308.13 | 350 | 107,844 | 1,596,582 | 1.6 M to 1.6 M (-0.02 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 307.06 | 14,640 | 4,495,314 | 1,596,932 | 1.6 M to 1.6 M (-0.91 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 306.23 | 525 | 160,772 | 1,611,572 | 1.6 M to 1.6 M (-0.03 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 305.14 | 1,732 | 528,501 | 1,612,097 | 1.6 M to 1.6 M (-0.11 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 303.77 | 1,193 | 362,394 | 1,613,829 | 1.6 M to 1.6 M (-0.07 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.55 | 1,100 | 332,806 | 1,615,022 | 1.6 M to 1.6 M (-0.07 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.42 | 1,710 | 515,426 | 1,616,122 | 1.6 M to 1.6 M (-0.11 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.21 | 3,985 | 1,196,329 | 1,617,832 | 1.6 M to 1.6 M (-0.25 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 298.61 | 100 | 29,861 | 1,621,817 | 1.6 M to 1.6 M (-0.01 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.76 | 9,985 | 2,973,134 | 1,621,917 | 1.6 M to 1.6 M (-0.61 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.86 | 6,192 | 1,838,139 | 1,631,902 | 1.6 M to 1.6 M (-0.38 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.21 | 7,062 | 2,091,814 | 1,638,094 | 1.6 M to 1.6 M (-0.43 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.96 | 3,254 | 959,800 | 1,645,156 | 1.6 M to 1.6 M (-0.20 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 4,468 | 1,312,908 | 1,648,410 | 1.7 M to 1.6 M (-0.27 %) |
Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.70 | 3,704 | 1,084,165 | 1,652,878 | 1.7 M to 1.7 M (-0.22 %) |
Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 1,656,582 | 1.7 M to 1.7 M (+0.02 %) |
May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 325 | 0 | 324 | |
May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 1,330 | 0 | 0 | |
May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 325 | 0 | 1,656,258 | 1.7 M to 1.7 M (+0.02 %) |
May 09 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 1,330 | 0 | 1,655,933 | 1.7 M to 1.7 M (+0.08 %) |
Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 320.00 | 81,305 | 26,017,600 | 1,654,603 | 1.7 M to 1.7 M (-4.68 %) |
Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
Feb 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 1,735,908 | 1.7 M to 1.7 M (+0.02 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | M | 0.17 | 327,133 | 55,613 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | J | 0.17 | 327,133 | 55,613 | 327,133 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | J | 0.17 | 327,133 | 55,613 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | M | 0.17 | 1,417,578 | 240,988 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | J | 0.17 | 1,417,578 | 240,988 | 1,417,578 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | J | 0.17 | 1,417,578 | 240,988 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 693,991 | 0 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 3,007,297 | 0 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 1,905,702 | 0 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 1,295,845 | 0 | 0 | |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 11.00 | 712,192 | 7,834,112 | 9,941,551 | 9.2 M to 9.9 M (+7.72 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Payment of Exercise | F | 11.00 | 5,116 | 56,276 | 9,229,359 | 9.2 M to 9.2 M (-0.06 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | M | 0.17 | 327,133 | 55,613 | 9,234,475 | 8.9 M to 9.2 M (+3.67 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Payment of Exercise | F | 11.00 | 22,166 | 243,826 | 8,907,342 | 8.9 M to 8.9 M (-0.25 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | M | 0.17 | 1,417,578 | 240,988 | 8,929,508 | 7.5 M to 8.9 M (+18.87 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 693,991 | 0 | 7,511,930 | 6.8 M to 7.5 M (+10.18 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 3,007,297 | 0 | 6,817,939 | 3.8 M to 6.8 M (+78.92 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,905,702 | 0 | 3,810,642 | 1.9 M to 3.8 M (+100.04 %) |
Nov 20 2013 | RLYP | Relypsa Inc | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,904,940 | 0 | 1,904,940 | 0 to 1.9 M |
Oct 31 2013 | MYG | Mirati Therapeutic ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 17.50 | 125,000 | 2,187,500 | 1,274,332 | 1.1 M to 1.3 M (+10.88 %) |
Nov 12 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 325 | 0 | 973 | |
Nov 12 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 325 | 0 | 1,735,584 | 1.7 M to 1.7 M (+0.02 %) |
Oct 23 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 62.50 | 40,088 | 2,505,500 | 1,735,259 | 1.8 M to 1.7 M (-2.26 %) |
Oct 17 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 62.50 | 376,585 | 23,536,563 | 1,775,347 | 2.2 M to 1.8 M (-17.50 %) |
Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 325 | 0 | 1,298 | |
Aug 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 325 | 0 | 2,151,932 | 2.2 M to 2.2 M (+0.02 %) |
May 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 1,623 | |
May 13 2013 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 2,151,607 | 2.2 M to 2.2 M (+0.02 %) |
May 24 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.99 | 120 | 839 | 14,067 | 13.9 K to 14.1 K (+0.86 %) |
May 24 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.99 | 12,380 | 86,528 | 1,476,702 | 1.5 M to 1.5 M (+0.85 %) |
May 24 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.86 | 200 | 1,372 | 13,947 | 13.7 K to 13.9 K (+1.45 %) |
May 24 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.86 | 21,100 | 144,767 | 1,464,322 | 1.4 M to 1.5 M (+1.46 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 18,795 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 1,973,439 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 50,256 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 5,276,702 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 83,959 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 8,815,565 | 0 | 0 | |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.90 | 80 | 552 | 13,747 | 13.7 K to 13.7 K (+0.59 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.90 | 8,020 | 55,314 | 1,443,222 | 1.4 M to 1.4 M (+0.56 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 8.00 | 590 | 4,720 | 13,667 | 13.1 K to 13.7 K (+4.51 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 8.00 | 61,910 | 495,280 | 1,435,202 | 1.4 M to 1.4 M (+4.51 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 8.00 | 5,653 | 45,224 | 13,077 | 7.4 K to 13.1 K (+76.14 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 8.00 | 593,618 | 4,748,944 | 1,373,292 | 779.7 K to 1.4 M (+76.14 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,730 | 0 | 7,424 | 5.7 K to 7.4 K (+30.38 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 181,689 | 0 | 779,674 | 598 K to 779.7 K (+30.38 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 2,094 | 0 | 5,694 | 3.6 K to 5.7 K (+58.17 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 219,863 | 0 | 597,985 | 378.1 K to 598 K (+58.15 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 3,498 | 0 | 3,600 | 102 to 3.6 K (+3,429.41 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 367,315 | 0 | 378,122 | 10.8 K to 378.1 K (+3,398.86 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.78 | 100 | 678 | 102 | 2 to 102 (+5,000.00 %) |
May 22 2013 | AMBI | AMBIT BIOSCIENCES ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 6.78 | 10,500 | 71,162 | 10,807 | 307 to 10.8 K (+3,420.20 %) |
Feb 01 2013 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Buy | P | 0.66 | 5,700,000 | 3,762,000 | 7,462,000 | 1.8 M to 7.5 M (+323.50 %) |
Jan 29 2013 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Buy | P | 0.65 | 1,762,000 | 1,142,481 | 1,762,000 | 0 to 1.8 M |
Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 10,500,000 | 0 | 0 | |
Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.00 | 333,334 | 5,000,010 | 2,150,634 | 1.8 M to 2.2 M (+18.34 %) |
Oct 16 2012 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,817,300 | 0 | 1,817,300 | 0 to 1.8 M |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.51 | 4,500 | 11,298 | 27,859 | 32.4 K to 27.9 K (-13.91 %) |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.51 | 474,800 | 1,192,033 | 2,922,141 | 3.4 M to 2.9 M (-13.98 %) |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.85 | 2,076 | 5,916 | 32,359 | 34.4 K to 32.4 K (-6.03 %) |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.85 | 218,624 | 622,991 | 3,396,941 | 3.6 M to 3.4 M (-6.05 %) |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.90 | 4,792 | 13,891 | 34,435 | 39.2 K to 34.4 K (-12.22 %) |
Jul 13 2012 | GNOM | COMPLETE GENOMICS ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 2.90 | 503,144 | 1,458,514 | 3,615,565 | 4.1 M to 3.6 M (-12.22 %) |
Jul 03 2012 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 0.73 | 1,283,300 | 942,071 | 0 | 1.3 M to 0 (-100.00 %) |
Sep 05 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 14.43 | 2,244 | 32,388 | 5,700 | 7.9 K to 5.7 K (-28.25 %) |
Sep 05 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 14.43 | 231,456 | 3,340,604 | 594,300 | 825.8 K to 594.3 K (-28.03 %) |
Jul 30 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 14.61 | 3,456 | 50,483 | 7,944 | 11.4 K to 7.9 K (-30.32 %) |
Jul 30 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 14.61 | 362,844 | 5,300,207 | 825,756 | 1.2 M to 825.8 K (-30.53 %) |
Jun 19 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 12.91 | 5,900 | 76,185 | 11,400 | 17.3 K to 11.4 K (-34.10 %) |
Jun 19 2012 | AMRN | AMARIN CORP PLC\UK | ORBIMED ADVISORS LLC | Director | Sell | S | 12.91 | 611,200 | 7,892,242 | 1,188,600 | 1.8 M to 1.2 M (-33.96 %) |
Mar 13 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.03 | 700 | 7,722 | 2,446,000 | 2.4 M to 2.4 M (-0.03 %) |
Mar 13 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.03 | 62,400 | 688,384 | 2,446,700 | 2.5 M to 2.4 M (-2.49 %) |
Mar 13 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.25 | 300 | 3,374 | 2,509,100 | 2.5 M to 2.5 M (-0.01 %) |
Mar 13 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.25 | 36,700 | 412,714 | 2,509,400 | 2.5 M to 2.5 M (-1.44 %) |
Feb 29 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 10.86 | 3,000 | 32,584 | 2,546,100 | 2.5 M to 2.5 M (-0.12 %) |
Feb 29 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.12 | 100 | 1,112 | 2,549,100 | 2.5 M to 2.5 M (0.00 %) |
Feb 29 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.12 | 10,000 | 111,204 | 2,549,200 | 2.6 M to 2.5 M (-0.39 %) |
Feb 29 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.05 | 300 | 3,314 | 2,559,200 | 2.6 M to 2.6 M (-0.01 %) |
Feb 29 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.05 | 28,700 | 317,055 | 2,559,500 | 2.6 M to 2.6 M (-1.11 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 10.79 | 500 | 5,395 | 2,588,200 | 2.6 M to 2.6 M (-0.02 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 10.79 | 49,500 | 534,125 | 2,588,700 | 2.6 M to 2.6 M (-1.88 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 10.85 | 200 | 2,171 | 2,638,200 | 2.6 M to 2.6 M (-0.01 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 10.85 | 23,100 | 250,746 | 2,638,400 | 2.7 M to 2.6 M (-0.87 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.01 | 700 | 7,704 | 2,661,500 | 2.7 M to 2.7 M (-0.03 %) |
Feb 03 2012 | PCRX | Pacira Pharmaceuti ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 11.01 | 69,300 | 762,702 | 2,662,200 | 2.7 M to 2.7 M (-2.54 %) |
Mar 22 2012 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 2.40 | 1,306,700 | 3,140,131 | 1,283,300 | 2.6 M to 1.3 M (-50.45 %) |
Mar 22 2012 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 2.87 | 125,000 | 358,313 | 2,590,000 | 2.7 M to 2.6 M (-4.60 %) |
Mar 22 2012 | ANTH | Anthera Pharmaceut ... | ORBIMED ADVISORS LLC | Director | Sell | S | 2.90 | 116,800 | 338,638 | 2,715,000 | 2.8 M to 2.7 M (-4.12 %) |
Page: 1